Scarica l'app Stockscreener
33.15
2.50%
0.81
Dopo l'orario di chiusura:
33.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
(SUPN) Trading Report - news.stocktradersdaily.com
Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD - GlobeNewswire
Jay Glazer and Wife Share Raw ADHD Story: How Treatment Changed Their Marriage - Stock Titan
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Supernus (SUPN) to Protect Qelbree Patents Amid Generic Challenges | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Faces Patent Challenges for Qelbree - TipRanks
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference | SUPN Stock News - GuruFocus
Supernus CEO Fireside Chat: Latest CNS Pipeline Insights Coming at Major Healthcare Conference - Stock Titan
Supernus Announces Paragraph IV ANDA Filings for Qelbree® | SUPN Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Investment Report - news.stocktradersdaily.com
Bank of America Corp DE Has $13.49 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrep - GuruFocus
Busy Philipps Partners with Supernus (SUPN) to Empower Women wit - GuruFocus
Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD - Nasdaq
Busy Philipps Empowers Women with ADHD to Go from Feeling - GlobeNewswire
Busy Philipps Reveals ADHD Journey: New Campaign Spotlights Hidden Women's Symptoms - Stock Titan
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals - The Manila Times
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com - Defense World
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality - simplywall.st
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Announces First Quarter 2025 Financial Results | SUPN S - GuruFocus
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):